Thursday, 15 October 2026European Markets

MAUREL ET PROM And PANORO ENERGY Have A High Dividend Yield And Return On Equity In The Oil & Gas E&P Industry.

Loading stream...

(vianews) - maurel et prom (mau.pa) is among this list of stock assets with the highest dividend rate and return on equity on the oil & gas e&p industry.

financial asset price forward dividend yield return on equity
maurel et prom (mau.pa) €4.74 4.7% 14.41%
panoro energy (pen.ol) kr29.00 2.78% 21.81%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. maurel et prom (mau.pa)

4.7% forward dividend yield and 14.41% return on equity

etablissements maurel & prom s.a., an oil and gas exploration company, engages in the exploration and production of hydrocarbons. it operates through three segments: exploration, production, and drilling. the company was founded in 1831 and is headquartered in paris, france. etablissements maurel & prom s.a. is a subsidiary of pt pertamina internasional eksplorasi dan produksi.

earnings per share

as for profitability, maurel et prom has a trailing twelve months eps of €0.57.

pe ratio

maurel et prom has a trailing twelve months price to earnings ratio of 8.32. meaning, the purchaser of the share is investing €8.32 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.41%.

volatility

maurel et prom's last week, last month's, and last quarter's current intraday variation average was a negative 2.45%, a negative 0.23%, and a positive 2.42%.

maurel et prom's highest amplitude of average volatility was 2.45% (last week), 1.75% (last month), and 2.42% (last quarter).

more news about maurel et prom.

2. panoro energy (pen.ol)

2.78% forward dividend yield and 21.81% return on equity

panoro energy asa, an independent exploration and production company, engages in the exploration, development, and production of oil and gas properties in africa. it holds assets in the equatorial guinea, gabon, tunisia, and south africa. the company was incorporated in 2009 and is based in london, the united kingdom.

earnings per share

as for profitability, panoro energy has a trailing twelve months eps of kr4.04.

pe ratio

panoro energy has a trailing twelve months price to earnings ratio of 7.18. meaning, the purchaser of the share is investing kr7.18 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 21.81%.

volume

today's last reported volume for panoro energy is 243490 which is 43.33% below its average volume of 429732.

revenue growth

year-on-year quarterly revenue growth grew by 2.3%, now sitting on 224.92m for the twelve trailing months.

growth estimates quarters

the company's growth estimates for the present quarter is a negative 63.2% and positive 566.3% for the next.

more news about panoro energy.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com